RESEARCHER PROFILE
Jill Adler‐Moore
← Back to California State Polytechnic University
J
California State Polytechnic University
Jill Adler‐Moore works in Antifungal resistance and susceptibility, Fungal Infections and Studies, Nanoparticle-Based Drug Delivery, Antibiotics Pharmacokinetics and Efficacy, Fungal and yeast genetics research. Recorded institutional associations include California State Polytechnic University.
64Publications
3,251Citations
26H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis
2006 · 345 citationsAmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
2002 · 339 citationsDevelopment, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B
1993 · 251 citationsPharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
1991 · 203 citationsThe Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
2018 · 170 citationsProtection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines
2006 · 134 citationsClinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
2019 · 132 citationsAmphotericin B lipid preparations: what are the differences?
2008 · 128 citationsFunctional Interrelationships between Cell Membrane and Cell Wall in Antimicrobial Peptide-Mediated Killing of Staphylococcus aureus
2005 · 118 citationsComparison between liposomal formulations of amphotericin B
2016 · 113 citationsAmBisome targeting to fungal infections.
1994 · 107 citationsFluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.
1996 · 103 citationsComparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B
1991 · 102 citationsIn vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry
2007 · 92 citationsPreclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B
2019 · 83 citationsTreatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)
1991 · 81 citationsTreatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin
2005 · 75 citationsComparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products
2007 · 73 citationsComparative Efficacies, Toxicities, and Tissue Concentrations of Amphotericin B Lipid Formulations in a Murine Pulmonary Aspergillosis Model
2006 · 72 citationsEffects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B
2007 · 58 citationsSingle-Dose AmBisome (Liposomal Amphotericin B) as Prophylaxis for Murine Systemic Candidiasis and Histoplasmosis
2000 · 51 citationsEffect of tissue penetration on AmBisome efficacy.
2003 · 48 citationsToxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice
2014 · 41 citationsLiposomal Amphotericin B and Echinocandins as Monotherapy or Sequential or Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus Infections
2010 · 30 citationsAlternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis
2004 · 29 citationsCharacterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine
2011 · 26 citationsFixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals
2019 · 26 citationsComparison of antifungal treatments for murine fusariosis
2006 · 25 citationsAntimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake ofCandida glabrataby murine epidermal Langerhans cells
1998 · 22 citationsTissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens
2017 · 18 citationsDifferences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B
2010 · 17 citationsLiposomal gD ectodomain (gD1–306) vaccine protects against HSV2 genital or rectal infection of female and male mice
2009 · 16 citationsRecombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis
2022 · 16 citationsDifferences in Efficacy and Cytokine Profiles following Echinocandin or Liposomal Amphotericin B Monotherapy or Combination Therapy for Murine Pulmonary or Systemic Aspergillus flavus Infections
2011 · 15 citationsEffect of testosterone and estrogen supplementation on the resistance to systemic Candida albicans infection in mice
2020 · 14 citationsEffect of Delta-9-Tetrahydrocannabinol on Mouse Resistance to Systemic Candida albicans Infection
2014 · 12 citationsMonomeric M2e antigen in VesiVax®liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e
2017 · 11 citationsUnilamellar liposomes for anticancer and antifungal therapy
1998 · 10 citationsPharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections
2019 · 10 citationsAmBisome®: Long Circulating Liposomal Formulation of Amphotericin B
1998 · 10 citationsStability and mode of action of AmBisome® (liposomal amphotericin B)
1994 · 8 citationsThe adjuvant effects of mycoviral dsRNA and polyinosinic:polycytidylic acid on the murine immune response
1985 · 5 citationsSubcellular particles in pathogenic fungi.
1985 · 4 citationsNovel Drug Delivery Systems for Antifungal Agents
2004 · 4 citationsCase Study
2005 · 3 citationsDifferences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B
2009 · 1 citationsComparative in vivo and in vitro distribution of DaunoXome and daunorubicin in P1798 lymphosarcoma cells
1994 · 0 citations1639. Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Strains
2018 · 0 citations626. An Inexpensive Quantitative Method for Testing Anti-Fungal Drug Activity Using the Invertebrate Caenorhabditis elegans
2018 · 0 citations1554. Nebulized Liposomal Amphotericin B for Treatment of Murine Pulmonary Mucormycosis
2019 · 0 citations
